Preliminary data from a long-term t...

Preliminary data from a long-term treatment contemplation with Raptiva (Genentech, Inc., southward San Francisco, CA, efalizumab, formerly Xanelim), an investigational psoriasis treatment, revealed that 791% of the cohort of bring under rules completing one year of therapy maintained 50% or greater improvement in Psoriasis Area and Severity Index (PASI) scores (PASI 50) Sixty-one percent of this cohort had 75% or greater PASI improvement (PASI 75)

For this open-label, long-term trial, 339 subdues received an initial three-month course of therapy consisting of weekly subcutaneous doses of 2